|
1
|
Greenberg AK, Yee H and Rom WN:
Preneoplastic lesions of the lung. Respir Res. 3(20)2002.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Mao Y, Yang D, He J and Krasna MJ:
Epidemiology of Lung Cancer. Surg Oncol Clin N Am. 25:439–445.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
Cancers in 185 Countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lemjabbar-Alaoui H, Hassan OU, Yang YW and
Buchanan P: Lung cancer: Biology and treatment options. Biochim
Biophys Acta. 1856:189–210. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bilfinger T, Keresztes R, Albano D and
Nemesure B: Five-Year Survival Among Stage IIIA Lung Cancer
Patients Receiving Two Different Treatment Modalities. Med Sci
Monit. 22:2589–2594. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Johnson ML and Patel JD: Chemotherapy and
targeted therapeutics as maintenance of response in advanced
non-small cell lung cancer. Semin Oncol. 41:93–100. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hui H, Wang M, Guo H, Wang Y and Shi B:
Poziotinib-induced cutaneous adverse reactions in the treatment of
non-small cell lung cancer: A case report. Int J Dermatol.
61:769–770. 2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Leonardi GC, Oxnard GR, Haas A, Lang JP,
Williams JS and Awad MM: Diabetic Ketoacidosis as an Immune-related
Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer. J
Immunother. 40:249–251. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ganapathy-Kanniappan S and Geschwind JF:
Tumor glycolysis as a target for cancer therapy: progress and
prospects. Mol Cancer. 12(152)2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhang L, Zhang Z and Yu Z: Identification
of a novel glycolysis-related gene signature for predicting
metastasis and survival in patients with lung adenocarcinoma. J
Transl Med. 17(423)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Smolle E, Leko P, Stacher-Priehse E, Brcic
L, El-Heliebi A, Hofmann L, Quehenberger F, Hrzenjak A, Popper HH,
Olschewski H and Leithner K: Distribution and prognostic
significance of gluconeogenesis and glycolysis in lung cancer. Mol
Oncol. 14:2853–2867. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Li X, Yang G, Li X, Zhang Y, Yang J, Chang
J, Sun X, Zhou X, Guo Y, Xu Y, Liu J and Bensoussan A: Traditional
Chinese medicine in cancer care: a review of controlled clinical
studies published in chinese. PLoS One. 8(e60338)2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Su XL, Wang JW, Che H, Wang CF, Jiang H,
Lei X, Zhao W, Kuang HX and Wang QH: Clinical application and
mechanism of traditional Chinese medicine in treatment of lung
cancer. Chin Med J (Engl). 133(24):2987–2997. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wei Z, Chen J, Zuo F, Guo J, Sun X, Liu D
and Liu C: Traditional Chinese Medicine has great potential as
candidate drugs for lung cancer: A review. J Ethnopharmacol.
300(115748)2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Mohammadlou H, Hamzeloo-Moghadam M, Yami
A, Feizi F, Moeinifard M and Gharehbaghian A: Britannin a
Sesquiterpene Lactone from Inula aucheriana Exerted an
Anti-leukemic Effect in Acute Lymphoblastic Leukemia (ALL) Cells
and Enhanced the Sensitivity of the Cells to Vincristine. Nutr
Cancer. 74:965–977. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lu H, Wu Z, Wang Y, Zhao D, Zhang B and
Hong M: Study on inhibition of Britannin on triple-negative breast
carcinoma through degrading ZEB1 proteins. Phytomedicine.
104(154291)2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Luo Y and Chen C: The roles and regulation
of the KLF5 transcription factor in cancers. Cancer Sci.
112:2097–2117. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhang H, Shao F, Guo W, Gao Y and He J:
Knockdown of KLF5 promotes cisplatin-induced cell apoptosis via
regulating DNA damage checkpoint proteins in non-small cell lung
cancer. Thorac Cancer. 10:1069–1077. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tung CH, Huang MF, Liang CH, Wu YY, Wu JE,
Hsu CL, Chen YL and Hong TM: alpha-Catulin promotes cancer stemness
by antagonizing WWP1-mediated KLF5 degradation in lung cancer.
Theranostics. 12:1173–1186. 2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lu X, Zhao N, Duan G, Deng Z and Lu Y:
Testis developmental related gene 1 promotes non-small-cell lung
cancer through the microRNA-214-5p/Kruppel-like factor 5 axis.
Bioengineered. 13:603–616. 2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Shi J, Yang C, An J, Hao D, Liu C, Liu J,
Sun J and Jiang J: KLF5-induced BBOX1-AS1 contributes to cell
malignant phenotypes in non-small cell lung cancer via sponging
miR-27a-5p to up-regulate MELK and activate FAK signaling pathway.
J Exp Clin Cancer Res. 40(148)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang YF, Zhang ZH, Li MY, Wang JY, Xing
Y, Ri M, Jin CH, Xu GH, Piao LX, Zuo HX, Jin HL, Ma J and Jin X:
Britannin stabilizes T cell activity and inhibits proliferation and
angiogenesis by targeting PD-L1 via abrogation of the crosstalk
between Myc and HIF-1alpha in cancer. Phytomedicine.
81(153425)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li K, Zhou Y, Chen Y, Zhou L and Liang J:
A novel natural product, britanin, inhibits tumor growth of
pancreatic cancer by suppressing nuclear factor-kappaB activation.
Cancer Chemother Pharmacol. 85:699–709. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Cui YQ, Liu YJ and Zhang F: The
suppressive effects of Britannin (Bri) on human liver cancer
through inducing apoptosis and autophagy via AMPK activation
regulated by ROS. Biochem Biophys Res Commun. 497:916–923.
2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Karlstaedt A, Barrett M, Hu R, Gammons ST
and Ky B: Cardio-Oncology: Understanding the Intersections Between
Cardiac Metabolism and Cancer Biology. JACC Basic Transl Sci.
6:705–718. 2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Danhier P, Banski P, Payen VL, Grasso D,
Ippolito L, Sonveaux P and Porporato PE: Cancer metabolism in space
and time: Beyond the Warburg effect. Biochim Biophys Acta Bioenerg.
1858:556–572. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hong H, Luo B, Xie Z, Li M, Xu Q, He Z and
Peng Z: Retracted: Britannin mediates apoptosis and glycolysis of
T-cell lymphoblastic lymphoma cells by AMPK-dependent autophagy. J
Biochem Mol Toxicol. e23211:2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Gong T, Cui L, Wang H, Wang H and Han N:
Knockdown of KLF5 suppresses hypoxia-induced resistance to
cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis
through inactivation of the PI3K/Akt/mTOR pathway. J Transl Med.
16(164)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Xia W, Bai H, Deng Y and Yang Y: PLA2G16
is a mutant p53/KLF5 transcriptional target and promotes glycolysis
of pancreatic cancer. J Cell Mol Med. 24:12642–12655.
2020.PubMed/NCBI View Article : Google Scholar
|
